Discussion
Experimental treatments for narcolepsy
Several therapies are currently under development for narcolepsy, including orexin receptor agonist agents. Therapies targeting specific disease symptoms are also being tested.
Alixorexton
Alixorexton is an oral therapy that’s being developed by Alkermes for the treatment of narcolepsy types 1 and 2.
AXS-12
AXS-12 is an oral therapy that’s being developed by Axsome Therapeutics for the treatment of narcolepsy.
ORX750
ORX750 is an oral therapy that’s being developed by Centessa Pharmaceuticals for the treatment of narcolepsy types 1 and 2.
Samelisant
Samelisant is an oral therapy that’s being developed by Suven Life Sciences for the treatment of narcolepsy.
TAK-360
TAK-360 is an oral therapy that’s being developed by Takeda Pharmaceuticals for the treatment of type 2 narcolepsy.
TRN-257
TRN-257 is an oral therapy that’s being developed by Tris Pharma for the treatment of excessive daytime sleepiness or cataplexy in people with narcolepsy.
